Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 354

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 354
---
 stock issuable upon conversion of convertible notes to the extent their effect would be anti-dilutive. Basic and diluted net income (loss) per share were the same for the nine months ended September 30, 2025 and 2024 and for the three months ended September 30, 2024.The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2025 and 2024 (in thousands, except share and per share data):Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Numerator:Net income (loss), basic and diluted$2,905 $(14,235)$(17,633)$(64,152)Denominator:Weighted-average shares of common stock outstanding, basic50,639,23147,782,61949,758,10447,316,789Effect of dilutive securities:Options to purchase common stock and restricted stock units6,339,795———Employee stock purchase plan contingently issuable14,815———Weighted-average shares of common stock outstanding, diluted56,993,84147,782,61949,758,10447,316,789Net income (loss) per share, basic$0.06 $(0.30)$(0.35)$(1.36)Net income (loss) per share, diluted$0.05 $(0.30)$(0.35)$(1.36)

10

The following outstanding potential dilutive shares have been excluded from the calculation of diluted net income (loss) per share for the periods presented due to their anti-dilutive effect:Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Options to purchase common stock and restricted stock units1,881,06011,853,26111,183,25211,853,261Common stock issuable upon conversion of convertible notes9,963,7119,964,2479,963,7119,964,247Employee stock purchase plan contingently issuable—69,10950,12469,109Total11,844,77121,886,61721,197,08721,886,617Recent Accounting Pronouncements Not Yet AdoptedFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date